journal article·2024-03Open access

The Effect of a Lipid Surface Coating on the Permeation of Upconverting Nanoparticles through a 3D Human Lung Epithelial Model

Doyoung Kim, Gabrielle A. Mandl, Marta Balkota, Jimmy Vernaz, Song Huang, Samuel Constant, Pierre Maechler, Christine DeWolf, John A. Capobianco, Luigi Bonacina

Advanced Functional Materials· Volume 34· Issue 11

Abstract

Abstract Preclinical studies of nanoparticles for pulmonary therapeutics are often performed on 2D cell cultures or in vitro models that do not include a mucus barrier. However, the mucus layer lining the lungs is an essential barrier for drugs to permeate in order to exert a therapeutic effect. Herein, the role of surface coating of lanthanide‐doped upconverting nanoparticles (UCNPs) and their interaction with the mucus barrier are explored using a patient‐derived 3D cell culture model. The upconverted emissions from the UCNPs are used to track them throughout the 3D model and study their localization as a function of administration time and mucus thickness. Positively charged, ligand‐free, and negatively charged, supported lipid bilayer‐coated UCNPs are evaluated. A substantial difference in the residence time in mucus and mucociliary clearance of each type of UCNP is observed in a realistic and relevant model. As such, these results underscore the need for preclinical investigations in tissue models, especially with respect to the surface properties of the nanoparticles under study.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems · Cystic Fibrosis Research Advances

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Physics Université de Genève Rue de l'Ecole‐de‐Médecine 20 Genève 1205 Switzerland

Department of Chemistry and Biochemistry & Center for NanoScience Research Concordia University 7141 Sherbrooke St. W. Montreal QC H4B 1R6 Canada

Department of Cell Physiology and Metabolism Université de Genève Rue Michel‐Servet 1 Genève 1206 Switzerland

Epithelix Sàrl Chemin des Aulx 18, Plan‐les‐Ouates Genève 1228 Switzerland

Funding

Natural Sciences and Engineering Research Council of Canada · H2020 LEIT Information and Communication Technologies

References (45)

Show source-provided references
1. 10.1021/acsnano.7b0485510.1021/acsnano.7b04855 ↗
2. 10.1021/acsnano.2c0924910.1021/acsnano.2c09249 ↗
3. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
4. 10.1021/acsbiomaterials.8b0035910.1021/acsbiomaterials.8b00359 ↗
5. 10.1021/acs.nanolett.8b0229110.1021/acs.nanolett.8b02291 ↗
6. 10.1021/acsbiomaterials.2c0004710.1021/acsbiomaterials.2c00047 ↗
7. 10.1021/cr020357g10.1021/cr020357g ↗
8. 10.1039/C1CS15187H10.1039/C1CS15187H ↗
9. 10.1002/adma.20090117410.1002/adma.200901174 ↗
10. 10.1039/D3NR00009E10.1039/D3NR00009E ↗
11. 10.1063/1.300558810.1063/1.3005588 ↗
12. 10.1007/4243_2020_1510.1007/4243_2020_15 ↗
13. 10.1039/c2cc33052k10.1039/c2cc33052k ↗
14. 10.1039/C8CC03101K10.1039/C8CC03101K ↗
15. 10.1016/j.ijpharm.2017.09.01810.1016/j.ijpharm.2017.09.018 ↗
16. 10.3390/biomedicines1009217910.3390/biomedicines10092179 ↗
17. 10.1016/j.ejpb.2020.01.01710.1016/j.ejpb.2020.01.017 ↗
18. 10.1016/j.ejpb.2017.12.01710.1016/j.ejpb.2017.12.017 ↗
19. 10.3390/ma1502068210.3390/ma15020682 ↗
20. C.Roper M.Hargrove K.Sullivan D.Wolf OECD Environment Health and Safety Publications Series on Testing and Assessment No. 367: 2022.
21. 10.3390/nano910137410.3390/nano9101374 ↗
22. 10.1021/acsnano.7b0199210.1021/acsnano.7b01992 ↗
23. 10.1021/acsami.1c1497510.1021/acsami.1c14975 ↗
24. 10.1002/pssc.20120045610.1002/pssc.201200456 ↗
25. 10.1021/acsanm.8b0139610.1021/acsanm.8b01396 ↗
26. 10.1002/ppsc.20160021810.1002/ppsc.201600218 ↗
27. 10.4155/tde-2015-000210.4155/tde-2015-0002 ↗
28. 10.1021/acs.langmuir.0c0241010.1021/acs.langmuir.0c02410 ↗
29. 10.1016/j.cbi.2022.11004810.1016/j.cbi.2022.110048 ↗
30. 10.1016/S0169-409X(01)00115-610.1016/S0169-409X(01)00115-6 ↗
31. 10.1016/j.biomaterials.2013.01.06410.1016/j.biomaterials.2013.01.064 ↗
32. 10.1016/j.addr.2008.09.00810.1016/j.addr.2008.09.008 ↗
33. 10.1016/j.addr.2017.10.01410.1016/j.addr.2017.10.014 ↗
34. 10.1016/j.mtcomm.2020.10169210.1016/j.mtcomm.2020.101692 ↗
35. 10.1016/j.nantod.2015.07.00210.1016/j.nantod.2015.07.002 ↗
36. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
37. 10.4155/tde-2021-007010.4155/tde-2021-0070 ↗
38. 10.2217/nnm-2019-025610.2217/nnm-2019-0256 ↗
39. 10.3390/pharmaceutics1211104210.3390/pharmaceutics12111042 ↗
40. 10.1016/j.ijpharm.2008.01.00810.1016/j.ijpharm.2008.01.008 ↗
41. 10.1039/C9NA00556K10.1039/C9NA00556K ↗
42. 10.1021/nl104192910.1021/nl1041929 ↗
43. 10.1089/aivt.2017.003510.1089/aivt.2017.0035 ↗
44. 10.1016/j.ejpb.2019.04.00210.1016/j.ejpb.2019.04.002 ↗
45. 10.1177/109158181455164710.1177/1091581814551647 ↗